ebook: Accelerate vaccine development
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
List view / Grid view
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
Solutions to aid understanding of cellular and molecular pathways in diabetes and translate these findings into prevention and treatment strategies.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
The latest ebook from Sartorius takes an in-depth look at the technologies and techniques that have been integral to developing the antibody discovery workflow, featuring a host of expert articles, interviews and application notes.
Researchers have found that over 80 percent of antibodies target sections of the SARS-CoV-2 Spike protein other than the RBD.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
In this short video we show an example of a 3D airway organoid model along with some interesting ways to get the most out of this type of assay.
A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.